id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-E-1246-0006,FDA,FDA-2012-E-1246,"Determination of Regulatory Review Period for Purposes of Patent
Extension; RESOLUTE INTEGRITY ZOTAROLIMUS–ELUTING CORONARY
STENT SYSTEM",Notice,General Notice,2014-05-28T04:00:00Z,2014,5,2014-05-28T04:00:00Z,,2014-05-28T14:22:05Z,2014-12295,0,0,0900006481718b6d
FDA-2012-E-1246-0005,FDA,FDA-2012-E-1246,Letter from FDA/CDER to U.S. Patent and Trademark Office,Other,Letter(s),2014-05-02T04:00:00Z,2014,5,2014-05-02T04:00:00Z,,2014-05-02T18:42:15Z,,0,0,09000064816dde85
FDA-2012-E-1246-0004,FDA,FDA-2012-E-1246,Letter from U.S. Patent and Trademark Office to Sterne Kessler Goldstein & Fox PLLC,Other,Letter(s),2014-04-01T04:00:00Z,2014,4,2014-04-01T04:00:00Z,,2014-04-01T15:52:32Z,,0,0,090000648169503b